No Detectable Differences in MicroRNA Plasma Levels Between Diabetic Hypertensive Patients with and Without Incident Subclinical Atrial Fibrillation

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 11

PMID 38731083

Authors

Soren Feddersen

Tine J Philippsen

Michael S Hansen

Lene S Christensen

Mads Nybo

Axel Brandes

Affiliations

Soon will be listed here.

Abstract

: Long-term rhythm monitoring (LTRM) can detect undiagnosed atrial fibrillation (AF) in patients at risk of AF and stroke. Circulating microRNAs (miRNAs), which have been shown to play a role in atrial electrical and structural remodelling, could help to select patients who would benefit most from LTRM. The aim of this study was to investigate whether patients with diabetes mellitus (DM) and hypertension and screen-detected subclinical AF (SCAF) using an insertable cardiac monitor (ICM) have significantly different plasma baseline levels of five selected miRNAs playing a role in the modulation of atrial electrical and structural remodelling (miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p) compared to those without SCAF. : This study was performed at the outpatient clinic of a secondary academic teaching hospital between December 2013 and November 2015. Eligible patients were ≥65 years of age with DM and hypertension but without known heart diseases. All patients received an ICM. On the day of ICM implantation, blood samples for the measurement of plasma levels of the five miRNAs were drawn. In this post hoc analysis, we investigated their expression by reverse transcription-quantitative polymerase chain reaction. MiRNA plasma levels in patients with and without newly detected SCAF were compared. : We included 82 consecutive patients (median age of 71.3 years (IQR 67.4-75.1)), who were followed for a median of 588 days (IQR: 453-712 days). Seventeen patients (20.7%) had ICM-detected SCAF. Plasma levels of miR-328-3p, miR-29b-3p, miR-21-5p, miR-432-5p, and miR-150-5p were slightly but not significantly different in patients with incident SCAF compared with patients without. : In patients with hypertension and DM, newly detected SCAF was not significantly associated with changes in expression levels of miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p.

References

Liu T, Zhong S, Rao F, Xue Y, Qi Z, Wu S . Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients. Europace. 2015; 18(1):92-9. DOI: 10.1093/europace/euu366. View

Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck K, Lebedev D . Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol. 2010; 3(2):141-7. DOI: 10.1161/CIRCEP.109.877852. View

Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E . Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med. 2010; 269(2):160-71. DOI: 10.1111/j.1365-2796.2010.02287.x. View

Li J, Wang L . B-type natriuretic peptide levels in patients with paroxysmal lone atrial fibrillation. Heart Vessels. 2006; 21(3):137-40. DOI: 10.1007/s00380-005-0884-y. View

Kara K, Geisel M, Mohlenkamp S, Lehmann N, Kalsch H, Bauer M . B-type natriuretic peptide for incident atrial fibrillation-The Heinz Nixdorf Recall Study. J Cardiol. 2014; 65(6):453-8. DOI: 10.1016/j.jjcc.2014.08.003. View

Wachter R, Lahno R, Haase B, Weber-Kruger M, Seegers J, Edelmann F . Natriuretic peptides for the detection of paroxysmal atrial fibrillation in patients with cerebral ischemia--the Find-AF study. PLoS One. 2012; 7(4):e34351. PMC: 3324530. DOI: 10.1371/journal.pone.0034351. View

Creemers E, Tijsen A, Pinto Y . Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ Res. 2012; 110(3):483-95. DOI: 10.1161/CIRCRESAHA.111.247452. View

OBrien J, Hayder H, Zayed Y, Peng C . Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. PMC: 6085463. DOI: 10.3389/fendo.2018.00402. View

Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F . MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010; 122(23):2378-87. DOI: 10.1161/CIRCULATIONAHA.110.958967. View

10.

Andrade J, Deyell M, Macle L, Wells G, Bennett M, Essebag V . Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. N Engl J Med. 2022; 388(2):105-116. DOI: 10.1056/NEJMoa2212540. View

11.

Wolf P, Abbott R, Kannel W . Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8):983-8. DOI: 10.1161/01.str.22.8.983. View

12.

Fan J, Cao H, Su L, Ling Z, Liu Z, Lan X . NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation. J Interv Card Electrophysiol. 2011; 33(1):93-100. DOI: 10.1007/s10840-011-9606-9. View

13.

Geurts S, Mens M, Bos M, Ikram M, Ghanbari M, Kavousi M . Circulatory MicroRNAs in Plasma and Atrial Fibrillation in the General Population: The Rotterdam Study. Genes (Basel). 2022; 13(1). PMC: 8775308. DOI: 10.3390/genes13010011. View

14.

Hussein A, Bartz T, Gottdiener J, Sotoodehnia N, Heckbert S, Lloyd-Jones D . Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm. 2015; 12(5):879-85. PMC: 4546831. DOI: 10.1016/j.hrthm.2015.01.020. View

15.

Philippsen T, Christensen L, Hansen M, Dahl J, Brandes A . Detection of Subclinical Atrial Fibrillation in High-Risk Patients Using an Insertable Cardiac Monitor. JACC Clin Electrophysiol. 2018; 3(13):1557-1564. DOI: 10.1016/j.jacep.2017.06.020. View

16.

de Los Reyes-Garcia A, Zapata-Martinez L, Aguila S, Lozano M, Martinez C, Gonzalez-Conejero R . microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation. Front Cardiovasc Med. 2023; 10:1135127. PMC: 9988920. DOI: 10.3389/fcvm.2023.1135127. View

17.

Qin S, Zhang C . MicroRNAs in vascular disease. J Cardiovasc Pharmacol. 2010; 57(1):8-12. PMC: 4517184. DOI: 10.1097/FJC.0b013e318203759b. View

18.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View

19.

Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J . qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8(2):R19. PMC: 1852402. DOI: 10.1186/gb-2007-8-2-r19. View

20.

Kirchhof P, Camm A, Goette A, Brandes A, Eckardt L, Elvan A . Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020; 383(14):1305-1316. DOI: 10.1056/NEJMoa2019422. View